Omecamtiv mecarbil - Amgen

Drug Profile

Omecamtiv mecarbil - Amgen

Alternative Names: AMG-423; CK-1827452; CK-452

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokinetics
  • Developer Amgen; Cytokinetics
  • Class Esters; Heart failure therapies; Organic chemicals; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Cardiac myosin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase II Acute heart failure; Heart failure
  • No development reported Angina pectoris; Cardiomyopathies

Most Recent Events

  • 18 Sep 2017 Pharmacodynamics data from the phase III COSMIC-HF trial Chronic heart failure released by Cytokinetics
  • 08 May 2017 Amgen completes the phase II trial in Heart failure in Japan (NCT02695420)
  • 01 May 2017 Pharmacokinetics data from the phase III COSMIC-HF trial Chronic heart failure released by Cytokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top